S&P 500 climbs, but Nvidia slip keeps lid on gains
Investing.com -- Becton Dickinson posted fourth-quarter earnings that came in slightly above expectations and offered guidance that also beat forecasts.
The medical device maker posted earnings per share (EPS) of $3.96, ahead of consensus estimates of $3.92. Revenue totaled $5.9 billion, broadly in line with the $5.91 billion consensus.
Sales rose 8.3% on a reported basis, 7.0% at constant exchange rates, and 3.9% organically.
Still, shares in the company 1.4% in premarket trading Thursday.
"Our resilient business model and commitment to commercial and operational execution enabled us to deliver 3.9% organic growth in New BD along with substantial adjusted margin and earnings growth in fiscal 2025," said Tom Polen, chairman, CEO, and president of BD.
"We remain on track to complete the combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026."
For fiscal 2026, Becton Dickinson expects earnings per share between $14.75 and $15.05, well above the analyst consensus of $14.38. The company projects low single-digit revenue growth at constant exchange rates.